Company intelligence / Profile preview

Oblique Therapeutics

Göteborg, Västra Götalands län, Swedenobliquet.com ↗

Ownership: Private
Employees: ~22
Development stage: Preclinical

Overview

The company is developing antibody medicines using their proprietary AbiProt® technology platform. No specific clinical results were mentioned in the search results.

Therapeutic areas: OncologyNeurology
Modalities: Antibodies
Industry: Biotech

Drug pipeline

9 assets

OB1

Preclinical

8 more assets in the full pipeline.

Request access →

Partnerships

A large US-based pharmaceutical companyEli Lilly and Companya leading animal health company

Beyond the preview

Go deeper on Oblique Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oblique Therapeutics.

Explore the full profile